blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2832367

EP2832367 - AGENT FOR PREVENTING OR TREATING GIANT CELL TUMOR OR CHONDROSARCOMA ARISING IN BONE/SOFT TISSUE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.05.2021
Database last updated on 15.07.2024
FormerThe patent has been granted
Status updated on  12.06.2020
FormerGrant of patent is intended
Status updated on  17.02.2020
FormerExamination is in progress
Status updated on  15.09.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Nippon Chemiphar Co., Ltd.
2-3, Iwamoto-cho 2-chome Chiyoda-ku
Tokyo 101-0032 / JP
[2015/06]
Inventor(s)01 / TAKEUCHI, Akihiko
c/o National University Corporation
Kanazawa University
Nu 7
Kakuma-machi
Kanazawa-shi Ishikawa 920-1164 / JP
02 / TSUCHIYA, Hiroyuki
c/o National University Corporation
Kanazawa University
Nu 7
Kakuma-machi
Kanazawa-shi Ishikawa 920-1164 / JP
 [2015/06]
Representative(s)Godemeyer Blum Lenze Patentanwälte Partnerschaft mbB - werkpatent
An den Gärten 7
51491 Overath / DE
[2020/29]
Former [2015/06]Godemeyer Blum Lenze Patentanwälte Partnerschaft mbB
werkpatent
An den Gärten 7
51491 Overath / DE
Application number, filing date13769796.718.03.2013
[2020/29]
WO2013JP57706
Priority number, dateJP2012007035126.03.2012         Original published format: JP 2012070351
JP2012023578425.10.2012         Original published format: JP 2012235784
[2015/06]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013146435
Date:03.10.2013
Language:JA
[2013/40]
Type: A1 Application with search report 
No.:EP2832367
Date:04.02.2015
Language:EN
[2015/06]
Type: B1 Patent specification 
No.:EP2832367
Date:15.07.2020
Language:EN
[2020/29]
Search report(s)International search report - published on:JP03.10.2013
(Supplementary) European search report - dispatched on:EP13.11.2015
ClassificationIPC:A61K45/00, A61K31/38, A61P35/00, G01N33/15, G01N33/50, G01N33/52, A61K31/167, A61K31/196, A61K31/405, A61K31/421, A61K31/427, A61K31/4439, A61K31/517
[2015/50]
CPC:
A61K31/4439 (EP,US); A61K45/00 (CN); A61K31/167 (EP,CN,US);
A61K31/192 (EP,CN,US); A61K31/196 (EP,CN,US); A61K31/38 (EP,CN,US);
A61K31/405 (EP,CN,US); A61K31/421 (EP,CN,US); A61K31/427 (EP,US);
A61K31/517 (EP,US); A61K45/06 (US); A61P19/00 (EP);
A61P19/02 (EP); A61P19/08 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P43/00 (EP); C12Q1/6876 (US);
G01N33/5023 (EP,US); C12Q2600/106 (US); C12Q2600/158 (US) (-)
Former IPC [2015/06]A61K45/00, A61K31/38, A61P35/00, G01N33/15, G01N33/50, G01N33/52
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MITTEL ZUR PRÄVENTION ODER BEHANDLUNG VON RIESENZELLENTUMOREN ODER CHONDROSARKOMEN IN KNOCHEN UND WEICHEM GEWEBE[2015/06]
English:AGENT FOR PREVENTING OR TREATING GIANT CELL TUMOR OR CHONDROSARCOMA ARISING IN BONE/SOFT TISSUE[2015/06]
French:AGENT POUR PRÉVENIR OU TRAITER UNE TUMEUR DE CELLULE GÉANTE OU UN CHONDROSARCOME SURVENANT DANS UN OS/TISSU MOU[2015/06]
Entry into regional phase20.10.2014Translation filed 
20.10.2014National basic fee paid 
20.10.2014Search fee paid 
20.10.2014Designation fee(s) paid 
20.10.2014Examination fee paid 
Examination procedure20.10.2014Examination requested  [2015/06]
03.06.2016Amendment by applicant (claims and/or description)
15.09.2017Despatch of a communication from the examining division (Time limit: M04)
24.01.2018Reply to a communication from the examining division
17.12.2018Despatch of a communication from the examining division (Time limit: M04)
23.04.2019Reply to a communication from the examining division
18.02.2020Communication of intention to grant the patent
08.06.2020Fee for grant paid
08.06.2020Fee for publishing/printing paid
08.06.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.09.2017
Opposition(s)16.04.2021No opposition filed within time limit [2021/25]
Fees paidRenewal fee
10.03.2015Renewal fee patent year 03
10.03.2016Renewal fee patent year 04
10.03.2017Renewal fee patent year 05
13.03.2018Renewal fee patent year 06
13.03.2019Renewal fee patent year 07
12.03.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.03.2013
AL15.07.2020
AT15.07.2020
CY15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
MK15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
LU18.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
[2024/22]
Former [2023/30]HU18.03.2013
AL15.07.2020
AT15.07.2020
CY15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
LU18.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
Former [2023/27]HU18.03.2013
AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
LU18.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
Former [2022/33]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
LU18.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
Former [2022/11]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
LU18.03.2021
CH31.03.2021
LI31.03.2021
Former [2022/09]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
LU18.03.2021
Former [2022/07]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
IE18.03.2021
Former [2021/45]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/36]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/28]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SK15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/25]AL15.07.2020
AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/23]AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
SM15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/22]AT15.07.2020
CZ15.07.2020
DK15.07.2020
EE15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SE15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/20]AT15.07.2020
DK15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
IT15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RS15.07.2020
SE15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/17]AT15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
NL15.07.2020
PL15.07.2020
RS15.07.2020
SE15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/10]AT15.07.2020
ES15.07.2020
FI15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
PL15.07.2020
RS15.07.2020
SE15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/09]AT15.07.2020
ES15.07.2020
FI15.07.2020
LT15.07.2020
SE15.07.2020
BG15.10.2020
NO15.10.2020
GR16.10.2020
PT16.11.2020
Former [2021/08]ES15.07.2020
FI15.07.2020
LT15.07.2020
SE15.07.2020
BG15.10.2020
NO15.10.2020
PT16.11.2020
Former [2021/07]FI15.07.2020
LT15.07.2020
NO15.10.2020
Documents cited:Search[A]WO2008026729  (UNIV CHIBA NAT UNIV CORP [JP], et al) [A] 1-14 * the whole document *;
 [XI]  - K. NISHIDA ET AL, "Chondrosarcoma and Peroxisome Proliferator-Activated Receptor", PPAR RESEARCH, US, (20080101), vol. 274, no. 24, doi:10.1200/JCO.2005.02.766, ISSN 1687-4757, pages 17088 - 7, XP055223868 [X] 1,3-5,7,9,11,13 * page 2, column r, paragraph 2 * * page 4, column r, paragraph 1 * * abstract * [I] 1-14

DOI:   http://dx.doi.org/10.1155/2008/250568
 [X]  - DE CHIARA ANNAROSARIA ET AL, "Multicentric giant cell tumor with viral-like inclusions associated with Paget's disease of bone: A case treated by steroid therapy", ONCOLOGY REPORTS, (199803), vol. 5, no. 2, ISSN 1021-335X, pages 317 - 320, XP009186928 [X] 1,2,4,7,8,11,12 * page 319, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.3892/or.5.2.317
 [T]  - R. YAMAZAKI ET AL, "Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Association with Activation of Peroxisome Proliferator-Activated Receptor gamma in Rheumatoid Synovial Cells", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, (20020701), vol. 302, no. 1, doi:10.1124/jpet.302.1.18, ISSN 0022-3565, pages 18 - 25, XP055224151

DOI:   http://dx.doi.org/10.1124/jpet.302.1.18
International search[X]JP2005200419  (NAT HEALTH RESEARCH INSTITUTES);
 [X]JP2005343802  (SAKAYAMA NORIFUMI);
 [X]JP2006501136  (PHARMACIA CORP.);
 [X]JP2009533467  (SMITHKLINE BEECHAM CORP.);
 [X]  - AKIHIKO TAKEUCHI ET AL., "Kotsukyo Saiboshu ni Taisuru PPARy (peroxisome proliferator- activated receptor y) Kasseika ni yoru Ko-Shuyo Koka", THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, (20120825), vol. 86, no. 8, page S1319, XP008174894
 [X]  - NISHIDA, K. ET AL., "Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor- gamma", BR J CANCER, (2002), vol. 86, no. 8, pages 1303 - 9, XP055168739

DOI:   http://dx.doi.org/10.1038/sj/bjc/6600241
 [X]  - VAISH, V. ET AL., "The role of NF-KB and PPARy in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors", TUMOR BIOL, (2010), vol. 31, no. 5, pages 427 - 36, XP055168743

DOI:   http://dx.doi.org/10.1007/s13277-010-0051-7
 [X]  - LIU, Y. ET AL., "Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375", MED ONCOL, (2006), vol. 23, no. 3, pages 393 - 402, XP055168750

DOI:   http://dx.doi.org/10.1385/MO:23:3:393
 [X]  - XIE, K. H. ET AL., "Rosiglitazone and ATRA on gastric cancer SGC7901 cell line proliferation in vitro", ZHONGGUO YISHI ZAZHI, (2010), vol. 12, no. 6, pages 743 - 7, XP008174893
by applicantWO2008026729
    - JPN. J. CANCER RES., (1999), vol. 90, pages 75 - 80
    - FEBS LETT., (1999), vol. 455, pages 135 - 139
    - BIOCHEM. PHARMACOL., (2011), vol. 82, pages 464 - 475
    - CANCER LETT., (2010), vol. 297, pages 65 - 74
    - MOL. PHARMACOL., (2007), vol. 72, pages 674 - 685
    - J. PHARMACOL. EXP. THER., (2002), vol. 302, pages 18 - 25
    - Molecular Cloning
    - EXP. OPIN. THER. PATENTS, (1996), vol. 6, no. 5, pages 441 - 456
    - Methods in ENZYMOLOGY, vol. 70
    - METHODS IN ENZYMOLOGY, vol. 73
    - METHODS IN ENZYMOLOGY, vol. 74
    - Immunochemical Techniques (Part D: Selected Immunoassays, vol. 84
    - Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods, vol. 92
    - METHODS IN ENZYMOLOGY, ACADEMIC PRESS, vol. 121
    - HENCH ET AL., BIOMED. MASTER. SYMP., (1972), vol. 2, page 117
    - AOKI ET AL., CERAMICS, (1975), vol. 10, page 469
    - BULL. INST. CHEM. RES. KYOTOUNI., (1982), vol. 60, page 260
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.